Search
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses.
Eliapixant
go.drugbank.com/drugs/DB21465InvestigationalEliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive
Cod liver oil
go.drugbank.com/drugs/DB11321ApprovedNutraceuticalVet approvedCod liver oil is extracted from the liver of cod fish and mainly consists of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Also being a rich source of vitamin A and D, cod liver oil can be taken orally ...
Phenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigationalPhenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA ap...
Mirococept
go.drugbank.com/drugs/DB06492ExperimentalIt is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation
Valsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigational[A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States.
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[L15027] On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) based on 95% efficacy in clinical trials and a similar safety profile to other viral vaccines over a span of approximately
Brimonidine
go.drugbank.com/drugs/DB00484ApprovedInvestigational[A178951] It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors.